Retina Implant AG’s Alpha IMS microchip has received NUB
innovation status and is now eligible for reimbursement by Germany’s statutory
health insurance system, according to a company press release.
statutory health insurance system, which insures 90% of German citizens,
reached an agreement with six German University clinics and teaching hospitals
to make the Alpha IMS microchip available to patients with late-stage retinitis
pigmentosa, the release said.
The wireless subretinal implant is placed under the retina,
in the macular region, and simulates functioning nerve cells in patients with late-stage
Alpha IMS received CE mark designation in the European
Union in July 2013, according to the release.